Illuminating somatostatin analog action at neuroendocrine tumor receptors

Trends in Pharmacological Sciences

Volumn 34, Issue 12, 2013, Pages 676-688

  Reubi, Jean Claude ^a   Schonbrunn, Agnes ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

lanreotide; octreotide; pasireotide; sst receptors

Indexed keywords

ANGIOPEPTIN; BIM 23A760; DG 3173; DOPASTATIN; G PROTEIN COUPLED RECEPTOR; KE 108; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; PLACEBO; PTR 3173; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOID; CARCINOID SYNDROME; CUSHING DISEASE; DRUG EFFICACY; ENDOCYTOSIS; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; INTERNALIZATION; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR REGRESSION;

LANREOTIDE; OCTREOTIDE; PASIREOTIDE; SST RECEPTORS;

ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 84889084502     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.10.001     Document Type: Review

References (160)

1. P. Brazeau Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone Science 179 1973 77 79
2. R. Guillemin Hypothalamic hormones a.k.a. hypothalamic releasing factors J. Endocrinol. 184 2005 11 28
3. A. Schonbrunn Somatostatin receptors W.J. Lennarz, M.D. Lane, The Encyclopedia of Biological Chemistry 2013 Elsevier 262 266
4. C. Viollet Somatostatinergic systems in brain: networks and functions Mol. Cell. Endocrinol. 286 2008 75 87
5. A. Stengel Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes Curr. Pharm. Des. 19 2013 98 105
6. J. Van Op den Bosch The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review Regul. Pept. 156 2009 1 8
7. L. de Lecea Cortistatin: a natural somatostatin analog J. Endocrinol. Invest. 28 Suppl. Int. 2005 10 14
8. S. Siehler Pharmacological profile of somatostatin and cortistatin receptors Mol. Cell. Endocrinol. 286 2008 26 34
9. N. Robas MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion J. Biol. Chem. 278 2003 44400 44404
10. A. Colao Resistance to somatostatin analogs in acromegaly Endocr. Rev. 32 2011 247 271
11. R.A. Feelders Medical therapy of acromegaly: efficacy and safety of somatostatin analogues Drugs 69 2009 2207 2226
12. D. Wynick Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995) Clin. Endocrinol. (Oxf.) 30 1989 385 388
13. A.H. Schonbrunn, and A.H. Tashijan Jr Characterization of functional receptors for somatostatin in rat pituitary cells in culture J. Biol. Chem. 253 1978 6473 6483
14. C.B. Srikant, and Y.C. Patel Receptor binding of somatostatin-28 is tissue specific Nature 294 1981 259 260
15. J.C. Reubi High affinity binding sites for a somatostatin-28 analog in rat brain Life Sci. 28 1981 2191 2198
16. J.C. Reubi Distribution of somatostatin receptors in the human brain: an autoradiographic study Neuroscience 18 1986 329 346
17. D. Hoyer Classification and nomenclature of somatostatin receptors Trends Pharmacol. Sci. 16 1995 86 88
18. M. Vanetti Cloning and expression of a novel mouse somatostatin receptor (SSTR2B) FEBS Lett. 311 1992 290 294
19. J. Cordoba-Chacon Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology Ann. N. Y. Acad. Sci. 1220 2011 6 15
20. M. Duran-Prado Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors J. Clin. Endocrinol. Metab. 94 2009 2634 2643
21. M.R. Gadelha Novel pathway for somatostatin analogs in patients with acromegaly Trends Endocrinol. Metab. 24 2013 238 246
22. 2A antibodies with somatostatin receptor autoradiography Am. J. Surg. Pathol. 29 2005 1642 1651
23. S. Park Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release Proc. Natl. Acad. Sci. U.S.A. 109 2012 19003 19008
24. R.K. Somvanshi, and U. Kumar Pathophysiology of GPCR homo- and heterodimerization: special emphasis on somatostatin receptors Pharmaceuticals 5 2012 417 446
25. J.C. Reubi, and A.M. Landolt High density of somatostatin receptors in pituitary tumors from acromegalic patients J. Clin. Endocrinol. Metab. 59 1984 1148 1151
26. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr. Rev. 24 2003 389 427
27. J.C. Reubi Local upregulation of neuropeptide receptors in host blood vessels around human colorectal cancers Gastroenterology 110 1996 1719 1726
28. J.C. Reubi Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs Blood 92 1998 191 197
29. 2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts J. Clin. Endocrinol. Metab. 84 1999 2942 2950
30. 2A receptors in human gastrointestinal tissue Gut 53 2004 1431 1436
31. M. Volante Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy Mod. Pathol. 20 2007 1172 1182
32. 2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 J. Clin. Endocrinol. Metab. 93 2008 4519 4524
33. M. Korner Somatostatin receptors subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting Am. J. Surg. Pathol. 36 2012 242 252
34. 2A in human tumors Am. J. Pathol. 153 1998 233 245
35. 5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4 Neuroendocrinology 94 2011 255 264
36. C. Pyke, and L.B. Knudsen The glucagon-like peptide-1 receptor - or not? Endocrinology 154 2013 4 8
37. M.C. Michel How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch. Pharmacol. 379 2009 385 388
38. 5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur. J. Nucl. Med. 28 2001 836 846
39. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting Eur. J. Nucl. Med. 30 2003 781 793
40. J.C. Reubi Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas Cancer Res. 50 1990 5969 5977
41. J.C. Reubi, and A.M. Landolt The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status J. Clin. Endocrinol. Metab. 68 1989 844 850
42. S. Corbetta Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression Eur. J. Clin. Invest. 31 2001 208 214
43. 2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly J. Clin. Endocrinol. Metab. 98 2013 E66 E71
44. M. Nakashima Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas Endocr. J. 56 2009 295 304
45. S.L. Fougner The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma Clin. Endocrinol. (Oxf.) 68 2008 458 465
46. 2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas Cancer Res. 68 2008 10163 10170
47. L.J. Hofland Somatostatin and somatostatin receptors in Cushing's disease Mol. Cell. Endocrinol. 286 2008 199 205
48. J. Bertherat Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study J. Clin. Endocrinol. Metab. 88 2003 5353 5360
49. A. Colao Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study J. Clin. Endocrinol. Metab. 94 2009 3746 3756
50. L.A. Frohman Somatostatin secretion and action in the regulation of growth hormone secretion Metabolism 39 Suppl. 2 1990 43 45
51. L.K. Kvols, and J.C. Reubi Metastatic carcinoid tumors and the malignant carcinoid syndrome Acta Oncol. 32 1993 197 201
52. H.R. Maecke, and J.C. Reubi Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment J. Nucl. Med. 52 2011 841 844
53. S. Pyronnet Antitumor effects of somatostatin Mol. Cell. Endocrinol. 286 2008 230 237
54. E.A. Woltering Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives Cancer Biother. Radiopharm. 18 2003 601 609
55. K. Sharma, and C.B. Srikant Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells Int. J. Cancer 76 1998 259 266
56. A.V. Schally Hypothalamic hormones and cancer Front. Neuroendocrinol. 22 2001 248 291
57. B.D. Koch, and A. Schonbrunn The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes Endocrinology 114 1984 1784 1790
58. Y-Z. Gu Development and use of a receptor antibody to characterize the interaction between somatostatin receptor sst1 and G proteins Mol. Pharmacol. 48 1995 1004 1014
59. 2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody Mol. Endocrinol. 11 1997 527 537
60. i protein family members revealed by dissecting SST5 coupling in human pituitary cells J. Cell Sci. 126 2013 638 644
61. A. Schonbrunn, and B.D. Koch Mechanism by which somatostatin inhibits pituitary hormone release S. Reichlin, Somatostatin: Basic and Clinical Status 1987 Plenum Press 121 135
62. + channels through protein dephosphorylation Nature 351 1991 570 573
63. B.D. Koch Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin J. Biol. Chem. 263 1988 216 225
64. B.D. Koch Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium J. Biol. Chem. 260 1985 13138 13145
65. B.D. Koch, and A. Schonbrunn Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. II. An increase in potassium conductance initiates somatostatin-induced inhibition of prolactin secretion J. Biol. Chem. 263 1988 226 234
66. A. Luini, and M.A. De Matteis Evidence that receptor-linked G protein inhibits exocytosis by a post-second-messenger mechanism in AtT-20 cells J. Neurochem. 54 1990 30 38
67. 2+-induced insulin secretion in permeabilized HIT-T15 cells Biochem. J. 270 1990 273 276
68. K.M. Betke GPCR mediated regulation of synaptic transmission Prog. Neurobiol. 96 2012 304 321
69. Y. Zhou Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma Mol. Cell. Endocrinol. 2013 10.1016/j.mce.2013.09.006
70. M.R. Gadelha Genetics of pituitary adenomas Front. Horm. Res. 41 2013 111 140
71. G. Mantovani GNAS imprinting and pituitary tumors Mol. Cell. Endocrinol. 326 2010 15 18
72. E. Resmini Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient J. Clin. Endocrinol. Metab. 92 2007 1592 1599
73. A.P. Casarini Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3 J. Endocrinol. Invest. 29 2006 826 830
74. P. Dent S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ Cell. Signal. 9 1997 539 549
75. D.B. Reardon Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness Mol. Endocrinol. 11 1997 1062 1069
76. T. Florio Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases Mol. Cell. Endocrinol. 286 2008 40 48
77. T. Florio Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors Front. Biosci. 13 2008 822 840
78. J.J. Tentler Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency Mol. Endocrinol. 11 1997 859 866
79. I. Drozdov Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia PLoS ONE 6 2011 e22457
80. A.C. Emery Rapgef2 connects GPCR-mediated cAMP signals to ERK activation in neuronal and endocrine cells Sci. Signal. 6 2013 ra51
81. 2B receptor expression in neuroendocrine tumours: potential targets for therapy Purinergic Signal. 8 2012 265 274
82. P.M. Germano PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells J. Mol. Neurosci. 39 2009 391 401
83. T. Cuny Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy Ann. N. Y. Acad. Sci. 1220 2011 60 70
84. K.S. Murthy Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-β3 by Gβγ and inhibition of adenylyl cyclase by Gαi1 and Gαo J. Biol. Chem. 271 1996 23458 23463
85. 2+ mobilization in rat AR42J pancreas cells Biochem. Biophys. Res. Commun. 214 1995 81 85
86. 2A receptor: the pan-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways Mol. Endocrinol. 24 2010 240 249
87. M.C. Zatelli SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma Endocrinology 146 2005 2692 2698
88. E. Hubina Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours Eur. J. Endocrinol. 155 2006 371 379
89. I.I. Van-Ham Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation J. Neurochem. 102 2007 1796 1804
90. M. Kidd Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines Cancer 113 2008 690 700
91. D. Cervia, and P. Bagnoli An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology Pharmacol. Ther. 116 2007 322 341
92. A. Ben-Shlomo, and S. Melmed Pituitary somatostatin receptor signaling Trends Endocrinol. Metab. 21 2010 123 133
93. M. Cakir Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 - molecular pathways J. Cell. Mol. Med. 14 2010 2570 2584
94. N. Hukovic Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation Endocrinology 137 1996 4046 4049
95. G. Tulipano Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes J. Biol. Chem. 279 2004 21374 21382
96. A. Schonbrunn Selective agonism in somatostatin receptor signaling and regulation Mol. Cell. Endocrinol. 286 2008 35 39
97. Z. Csaba Molecular mechanisms of somatostatin receptor trafficking J. Mol. Endocrinol. 48 2012 R1 R12
98. 2A somatostatin receptor J. Biol. Chem. 272 1997 13869 13876
99. G. Elberg Homologous and heterologous regulation of somatostatin receptor 2 Mol. Endocrinol. 16 2002 2502 2514
100. 2 receptors in somatostatin target tissues J. Nucl. Med. 50 2009 936 941
101. 2 receptors in neuroendocrine tumors of octreotide-treated patients J. Clin. Endocrinol. Metab. 95 2010 2343 2350
102. 2A somatostatin receptor J. Biol. Chem. 275 2000 5591 5599
103. 2A) phosphorylation Mol. Pharmacol. 76 2009 68 80
104. 2A somatostatin receptor phosphorylation Mol. Endocrinol. 24 2010 436 446
105. M. Ghosh, and A. Schonbrunn Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation J. Biol. Chem. 286 2011 13561 13573
106. 2A somatostatin receptor control internalization, desensitization, and arrestin binding Mol. Pharmacol. 73 2008 292 304
107. V.V. Gurevich Arrestins as multi-functional signaling adaptors Handb. Exp. Pharmacol. 186 2008 15 37
108. 2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists Mol. Endocrinol. 25 2011 1040 1054
109. F. Poll Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling J. Biol. Chem. 286 2011 32931 32936
110. Q. Liu In vivo phosphorylation of the somatostatin 2A receptor in human tumors J. Clin. Endocrinol. Metab. 88 2003 6073 6079
111. 2 receptors in neuroendocrine tumors after octreotide treatment of patients Am. J. Pathol. 180 2012 1942 1949
112. E. Peverelli The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation Mol. Endocrinol. 22 2008 676 688
113. 5 somatostatin receptor Mol. Endocrinol. 27 2013 671 682
114. A. Roth Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization J. Biol. Chem. 272 1997 23769 23774
115. 2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives Endocrinology 138 1997 296 306
116. 1). Relationship to desensitization and internalization J. Biol. Chem. 276 2001 3709 3717
117. D. Roosterman Agonist-induced endocytosis of rat somatostatin receptor 1 Endocrinology 148 2007 1050 1058
118. 4 receptors Br. J. Pharmacol. 125 1998 833 841
119. H.J. Kreienkamp Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331) DNA Cell Biol. 17 1998 869 878
120. A.J. Butcher Physiological role of G-protein coupled receptor phosphorylation Handb. Exp. Pharmacol. 208 2012 79 94
121. A.J. Butcher Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code J. Biol. Chem. 286 2011 11506 11518
122. G. Weckbecker Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat. Rev. Drug Discov. 2 2003 999 1017
123. W. Bauer SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci. 31 1982 1133 1141
124. J. Pless Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin Scand. J. Gastroenterol. 21 Suppl. 119 1986 54 64
125. J.C. Reubi Evidence for two somatostatin-14 receptor types in rat brain cortex Neurosci. Lett. 49 1984 259 263
126. J.C. Reubi New specific radioligand for one subpopulation of brain somatostatin receptors Life Sci. 36 1985 1829 1836
127. R. Maurer, and J.C. Reubi Brain somatostatin receptor subpopulation visualized by autoradiography Brain Res. 333 1985 178 181
128. K.E. Oberg Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy Gastroenterology 139 2010 742 753
129. A. Rinke Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group J. Clin. Oncol. 27 2009 4656 4663
130. J.S. Bevan Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly J. Clin. Endocrinol. Metab. 90 2005 1856 1863
131. J. Strosberg, and L. Kvols Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors World J. Gastroenterol. 16 2010 2963 2970
132. M. Hejna The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Oncol. 13 2002 653 668
133. J.C. Reubi A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors Eur. J. Pharmacol. 456 2002 45 49
134. L.K. Kvols Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study Endocr. Relat. Cancer 19 2012 657 666
135. A. Colao A 12-month phase 3 study of pasireotide in Cushing's disease N. Engl. J. Med. 366 2012 914 924
136. M. Afargan Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin Endocrinology 142 2001 477 486
137. U. Plockinger DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours Eur. J. Endocrinol. 166 2012 223 234
138. M.D. Culler Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors Horm. Metab. Res. 43 2011 854 857
139. ClinicalTrials.gov (2010) Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA) (http://clinicaltrials.gov/show/NCT00994214)
140. Ipsen (2010) Ipsen Closes its BIM 23A760 Trials, 15 December (http://www.ipsen.com/wp-content/uploads/2013/03/PR-Ipsen-BIM-23A760-EN-FINAL. pdf)
141. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
142. Q. Liu Receptor signaling and endocytosis are differentially regulated by somatostatin analogs Mol. Pharmacol. 68 2005 90 101
143. S. Lesche Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro J. Clin. Endocrinol. Metab. 94 2009 654 661
144. R.A. Feelders Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors Drugs Today (Barc.) 49 2013 89 103
145. R.R. Henry Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers J. Clin. Endocrinol. Metab. 98 2013 3446 3453
146. 2A in human pancreatic islets J. Clin. Endocrinol. Metab. 83 1998 3746 3749
147. B. Kailey SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells Am. J. Physiol. Endocrinol. Metab. 303 2012 E1107 E1116
148. D.J. Kwekkeboom Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J. Clin. Oncol. 26 2008 2124 2130
149. J.C. Reubi, and H.R. Maecke Peptide-based probes for cancer imaging J. Nucl. Med. 49 2008 1735 1738
150. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur. J. Nucl. Med. Mol. Imaging 32 2005 724
151. D. Wild DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur. J. Nucl. Med. Mol. Imaging 30 2003 1338 1347
152. D. Wild Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors J. Nucl. Med. 54 2013 364 372
153. M. Ginj New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting Clin. Cancer Res. 14 2008 2019 2027
154. U. Eberlein Biodistribution and dosimetry of [68Ga]-DOTASOM targeting somatostatin receptors in a pig model Eur. J. Nucl. Med. Mol. Imaging 39 Suppl. 2 2012 S325
155. 0]LTT-SS28 Eur. J. Nucl. Med. 37 Suppl. 2 2010 S299
156. 111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study EJNMMI Res. 2 2012 25
157. 5 receptors: effects of somatostatin agonists and antagonists J. Nucl. Med. 47 2006 502 511
158. M. Ginj Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc. Natl. Acad. Sci. U.S.A. 103 2006 16436 16441
159. D. Wild First clinical evaluation of somatostatin receptor antagonist imaging J. Nucl. Med. 51 Suppl. 2 2010 483
160. 2-selective somatostatin antagonists suitable for radiotargeting J. Med. Chem. 51 2008 4030 4037